Methods and compositions for improving anti-angiogenic therapy with anti-integrins

摘要

A combination of a first agent that is bevacizumab and a second agent that is an antibody that specifically binds to beta 1 integrin associated with any alpha subunit and inhibits the binding of tumor cells to an extracellular substrate and blocks beta 1 integrin binding to Use in the treatment of cancer.